<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701529</url>
  </required_header>
  <id_info>
    <org_study_id>2018-09-004</org_study_id>
    <nct_id>NCT03701529</nct_id>
  </id_info>
  <brief_title>Effect of Anesthetic Agents on Optic Nerve Sheath Diameter</brief_title>
  <official_title>Effect of Anesthetic Agents (Propofol, Sevoflurane) on Optic Nerve Sheath Diameter(ONSD) in Patients Undergoing Robot-assisted Laparoscopic Gynecology Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hallym University Kangnam Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hallym University Kangnam Sacred Heart Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is to evaluate the effect of anesthetic agents ( propofol , sevoflurane) on
      intracranial pressure of female patients undergoing laparoscopic-robotic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anesthetic agents (propofol and sevoflurane)have different effect on intracranial pressure.
      Sevoflurane when used over 0.5 minimum alveolar concentration, dilates intracranial
      vasculature and increases intracranial pressure. On the other hand, propofol decreases
      intracranial blood pressure and intracranial pressure is maintained or decreases.

      Optic nerve sheath diameter is a feasible diagnostic tool in evaluating intracranial
      pressure. Female patients undergoing robot-assisted laparoscopic hysterectomy or myomectomy
      are evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Actual">September 16, 2019</completion_date>
  <primary_completion_date type="Actual">September 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>difference of optic nerve sheath diameter</measure>
    <time_frame>During the operation.</time_frame>
    <description>optic nerve sheath diameter is measured using sonographic probe. (10 minutes after induction of anesthesia/ 5 minutes after pneumoperitoneum and trendelenburg position / 20 minutes after pneumoperitoneum and trendelenburg position / 40 minutes after pneumoperitoneum and trendelenburg position / skin closure)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Uterus Myoma</condition>
  <condition>Uterine Cancer</condition>
  <arm_group>
    <arm_group_label>Sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.5-2.5 vol% of sevoflurane is used for maintenance of anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2-5 mcg/ml of propofol is used continuously for maintenance of anesthesia using target-controlled infusion system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>1.5-2.5 vol % sevoflurane is used for maintenance of anesthesia.</description>
    <arm_group_label>Sevoflurane</arm_group_label>
    <other_name>sevoflurane anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>2-5 mcg/ml of propofol is used for maintenance of anesthesia.</description>
    <arm_group_label>Propofol</arm_group_label>
    <other_name>propofol anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female patients undergoing robot-assisted laparoscopic hysterectomy or myomectomy

        Exclusion Criteria:

          -  history of brain hemorrhage or brain infarction

          -  liver disease or end stage renal disease

          -  glaucoma or any signs of increased intraocular pressure

          -  combined wtih other types of operation

          -  patient refusal

          -  weight less than 40 kg or over 100 kg
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choi Eun-Mi, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Kangnam Sungshim Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kangnam Sungshim Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 8, 2018</study_first_submitted>
  <study_first_submitted_qc>October 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2018</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

